Provided by Tiger Trade Technology Pte. Ltd.

Merck

152.55
+3.562.39%
Pre-market: 152.44-0.1100-0.07%08:17 EDT
Volume:15.98M
Turnover:2.44B
Market Cap:376.37B
PE:119.85
High:154.49
Open:149.12
Low:148.59
Close:148.99
52wk High:154.49
52wk Low:77.58
Shares:2.47B
Float Shares:2.47B
Volume Ratio:1.07
T/O Rate:0.65%
Dividend:3.32
Dividend Rate:2.18%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.98
PE(LYR):20.95

Loading ...

Merck Initiated at Outperform by CICC

Dow Jones
·
Jun 25

Unicef, Gavi Call to Speed Bundibugyo Ebola Vaccine Access

Reuters
·
Jun 25

Merck says EC approves Keytruda plus Padcev combination

TIPRANKS
·
Jun 24

EU Approves Merck Keytruda Plus Padcev for Cisplatin-ineligible Resectable Muscle-invasive Bladder Cancer

Reuters
·
Jun 24

European Commission Approves Keytruda® (pembrolizumab) Plus Padcev® (enfortumab Vedotin-ejfv) as First Pd-1 Inhibitor Plus Antibody-drug Conjugate Regimen for Adults with Cisplatin-ineligible Resectable Muscle-invasive Bladder Cancer

THOMSON REUTERS
·
Jun 24

PharmaMar’s Partner Merck Seeks Priority Approval in Japan for Zepzelca as First-Line SCLC Maintenance

TIPRANKS
·
Jun 24

CICC Initiates Merck & Co. at Outperform With $138 Price Target

MT Newswires Live
·
Jun 24

Merck initiated with an Outperform at CICC

TIPRANKS
·
Jun 24

Movement Alert|Merck Rises 3.03% in Regular Trading, Multiple Catalysts Including Phase 3 Trial Success and Potential Major Acquisition

Market Focus
·
Jun 24

Scotiabank Reaffirms Their Buy Rating on Merck & Company (MRK)

TIPRANKS
·
Jun 23

Citi Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Jun 23

Merck (MRK) Stock Could Be 11% Undervalued After June Pipeline Wins

Simply Wall St.
·
Jun 23

Spanish stocks - Factors to watch on June 23

Reuters
·
Jun 23

Berenberg Bank Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Jun 23

Merck & Co. Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Jun 23

Merck's bowel disease drug meets main goal in late-stage trial

Reuters
·
Jun 22

Merck's Tulisokibart Hits Key Goals in Phase 3 Ulcerative Colitis Study

Dow Jones
·
Jun 22

Merck announces ‘positive’ results from Phase 3 trial of tulisokibart

TIPRANKS
·
Jun 22

Merck says Phase 3 trial shows tulisokibart meets primary endpoint in ulcerative colitis study

Reuters
·
Jun 22

Merck & Co - No Safety Concerns Identified in Phase 3 Atlas-Uc Study of Tulisokibart

THOMSON REUTERS
·
Jun 22